Introduction
============

Cancer is a global health problem associated with increasing mortality rates, in spite of advances in diagnostic and therapeutic approaches.[@b1-cmar-10-4491] Several pathological parameters and specific blood tumor markers have been proposed as predictive prognostic factors in cancer.[@b2-cmar-10-4491],[@b3-cmar-10-4491] However, the high incidence of cancer-related deaths indicates a need for reliable and efficient biomarkers for patient stratification and treatment selection.

Human epididymis protein 4 (HE4), also known as whey-acidic-protein four-disulfide core protein-2 (WFDC2), is a member of the protease inhibitor family with immune protective effects and is a promising novel cancer biomarker.[@b4-cmar-10-4491],[@b5-cmar-10-4491] HE4 has been approved by the US Food and Drug Administration as a new tumor marker for the diagnosis of early stage ovarian cancer.[@b6-cmar-10-4491] Several cancer types[@b7-cmar-10-4491]--[@b9-cmar-10-4491] are associated with HE4 overexpression in the serum and tissues. HE4 overexpression is also associated with cancer progression, and its prognostic value has been investigated in several published studies. However, the results remain controversial, and therefore this meta-analysis was performed to accurately assess the prognostic value of HE4 expression in cancer patients.

Materials and methods
=====================

Search strategy
---------------

The research databases PubMed, Web of Science, Chinese National Knowledge Infrastructure and WangFang databases were searched independently by two authors (Cong Dai and Yi Zheng) to obtain all relevant papers published as of August 2017. The following search terms were used: "Human Epididymis Protein 4 or HE4" and "neoplasms or cancer or tumor" and "prognosis." No language restrictions were applied. Furthermore, references within the retrieved relevant articles were screened to identify potentially eligible studies. Disagreements were resolved by iteration, discussion, and consensus between the two authors.

Inclusion and exclusion criteria
--------------------------------

Studies were considered eligible for inclusion if they met the following criteria: 1) studies evaluated the relationship of HE4 expression in patients with cancer with detailed information about overall survival (OS), disease-free survival (DFS), or progression-free survival (PFS); 2) selected cancer cases were pathologically confirmed, and 3) the study provided a hazard ratio (HR) with the corresponding confidence interval (CI), or sufficient data to calculate it. The exclusion criteria were as follows: 1) duplicate publications; 2) animal studies; 3) articles without usable data; 4) reviews, case reports, letters, and conference abstracts without original data.

Data extraction
---------------

Two independent reviewers (Cong Dai and Yi Zheng) extracted the details of included studies using a standardized form, and any disagreements were resolved through discussion with a third reviewer (Zhijun Dai). The following information was recorded: first author's surname, year of publication, number of patients, patient source, tumor types, HE4 assessment method, sample, prognostic outcomes, analytical method, and HR with the corresponding 95% CI.

Methodological quality of the studies
-------------------------------------

Quality assessment of included studies was conducted independently by two authors (Cong Dai and Tian Tian) following the Newcastle--Ottawa Scale (NOS) criteria,[@b10-cmar-10-4491] and any disagreements were resolved by discussion with a third reviewer (Zhijun Dai). The NOS criteria were scored on the basis of three aspects: 1) subject selection, 2) comparability of subject, and 3) clinical outcome. NOS scores may range from 0 to 9, and a score ≥6 indicates high quality.

Statistical methods
-------------------

Included studies were divided into three groups on the basis of the parameter that was reported: OS, DFS, and PFS. According to the cutoff values provided by the authors of each study, HE4 expression was designated as "high" or "low." HR and 95% CI were used to assess the association between HE4 expression and OS, DFS, and PFS. HRs obtained from studies were used directly in further analyses. For studies where HR values were not included explicitly, Kaplan--Meier survival curves or other methods were used to derive HRs from available data.[@b11-cmar-10-4491] Data from the Kaplan--Meier survival curves were read using the Engauge Digitizer version 4.1 software. Heterogeneity among studies was determined by the χ^2^ test and *Q* test. If there was no significant heterogeneity (*I*^2^≤50% or *P*≥0.05), a fixed-effect model was used; if significant heterogeneity was found to exist (*I*^2^\>50% or *P*\<0.05), a random-effects model was used. We further conducted subgroup analyses by race, tumor type, sample, method, and HR estimate. Sensitivity analysis was performed by omitting individual studies to examine the reliability of the results. Probable publication bias was assessed by Egger's and Begg's test.[@b12-cmar-10-4491],[@b13-cmar-10-4491] All *P*-values were two-sided, and *P*\<0.05 was considered statistically significant. Statistical calculations were performed using STATA 14.0 (StataCorp LLC, College Station, TX, USA).

Results
=======

Search results and study characteristics
----------------------------------------

A total of 369 articles from the primary literature were searched in PubMed, Web of Science, CNKI, and WangFang databases. References within the retrieved relevant articles had been screened, but there were no more potentially eligible studies. As shown in [Figure 1](#f1-cmar-10-4491){ref-type="fig"}, 340 studies were excluded because they were irrelevant to the analysis or because the primary outcome was insufficient. Finally, 29 available studies were included in this meta-analysis.[@b7-cmar-10-4491]--[@b9-cmar-10-4491],[@b14-cmar-10-4491]--[@b39-cmar-10-4491]

The characteristics of the 29 studies are summarized in [Table 1](#t1-cmar-10-4491){ref-type="table"}. Of the 29 publications, 23 assessed the relationship between HE4 expression and OS, eight studies evaluated the association between HE4 expression and DFS, and eleven evaluated PFS. A total of 4,235 patients from People's Republic of China, the Netherlands, Italy, Denmark, United States of America, France, Australia, Germany, Japan, Canada, Korea, and Sweden were enrolled with sample numbers ranging from 23 to 373. HE4 status in tumors was assessed by various methods: immunohistochemistry (IHC) (6 studies), electrochemiluminescence immunoassay assay (ECLIA) (2 studies), enzyme immu noassay assay (EIA) (15 studies), and Chemiluminesent Microparticle Immunoassay (CMIA) (5 studies). Study quality assessment, as per the Newcastle--Ottawa quality assessment scale, yielded scores ranging from 6 to 9, with a mean score of 7.6.

Quantitative synthesis
----------------------

### HE4 expression and OS in cancers

Overall, 23 studies, including 3,564 patients, reported a relationship between OS and HE4 expression level. As heterogeneity among the studies was statistically significant (*P*=0.001, *I*^2^=55.6%), a random-effects model was used. The pooled HR for OS showed that the overexpression of HE4 was significantly associated with reduced OS in cancers (HR =2.15, 95% CI =1.77--2.62, *P*\<0.001, [Table 2](#t2-cmar-10-4491){ref-type="table"} and [Figure 2](#f2-cmar-10-4491){ref-type="fig"}).

We also performed subgroup analysis as per race, tumor type, sample, analysis method, and HR estimate ([Table 2](#t2-cmar-10-4491){ref-type="table"}). Subgroup analysis showed that the correlation between OS and HE4 expression did not differ by race (White: HR =1.92, 95% CI =1.53--2.39, *P*\<0.001; Asian: HR =2.62, 95% CI =2.06--3.35, *P*\<0.001) and tumor type (endometrial cancer: HR =2.91, 95% CI =1.86--4.53, *P*\<0.001; ovarian cancer: HR =1.82, 95% CI =1.50--2.22, *P*\<0.001; lung cancer: HR =2.31, 95% CI =1.54--3.47, *P*\<0.001). Subgroup analysis, based on pooled data pertaining to sample, method, and HR estimate, also demonstrated that there was a significant association between OS and HE4 expression. Subgroup analysis of HR estimates found no significant heterogeneity (multivariate analysis: *I*^2^=13.4, univariate analysis: *I*^2^=47.8).

Included studies were sequentially removed to investigate whether any single study could have an influence on the pooled results. The results of the sensitivity analyses showed ([Figure 3](#f3-cmar-10-4491){ref-type="fig"}) that there was no influence of any single study on stable pooled HR.

### HE4 expression and DFS in cancers

Eight studies, with a total of 1,296 patients, provided results pertaining to DFS. There was no significant heterogeneity (*P*=0.757, *I*^2^=0.0%) among the studies, so a fixed-effect model was used to calculate the pooled HR and 95% CI. Our results showed that increased HE4 expression was significantly associated with poorer DFS (HR =2.50, 95% CI =1.86--3.37, *P*\<0.001) ([Figure 4](#f4-cmar-10-4491){ref-type="fig"}).

### HE4 expression and PFS in cancers

As shown in [Figure 5](#f5-cmar-10-4491){ref-type="fig"}, there were eleven studies, comprising a total of 1,291 patients, that provided results regarding PFS. The pooled data demonstrated that there was a significant association between HE4 expression and PFS (HR =1.27, 95% CI =1.11--1.45, *P*=0.001). There was no significant heterogeneity (*P*=0.070, *I*^2^=41.8%) among the studies, so a fixed-effect model was used.

### Publication bias

In this meta-analysis, both the Begg's and the Egger's tests were performed to assess if any publication bias existed in the included studies. Publication bias was observed in studies reporting OS (*P*=0.051, 0.000) and PFS (*P*=0.755, 0.003) but not in those reporting DFS (*P*=0.174, 0.149). The Begg's plots for the effect of HE4 expression level on OS are shown in [Figure 6](#f6-cmar-10-4491){ref-type="fig"}.

Discussion
==========

HE4 is a new tumor biomarker, which has been a subject of intense research in recent years. HE4, originally discovered by Kirchhoff in the human distal epididymal epithelial cells,[@b40-cmar-10-4491] is located on chromosome 20 at 20q12-13 and contains five exons and four introns.[@b41-cmar-10-4491] It contains a gene encoding protein domains that have homology with whey acidic protein, by which the product encoded is mainly protease inhibitor.[@b42-cmar-10-4491] As a member of the protease inhibitor family, it has an inhibitory effect on cell proliferation. Previous studies have reported that HE4 overexpression significantly promotes tumor cell apoptosis and adhesion and inhibits cell proliferation, migration, and invasiveness.[@b43-cmar-10-4491] Further, Kong et al[@b44-cmar-10-4491] found in vitro that this antitumor effect may be achieved by regulating the mitogen-activated protein kinase and phosphoinositide 3-kinase/AKT signal transduction pathways. Recently, further studies have been carried out to investigate the association between HE4 overexpression and prognosis in several tumors.[@b45-cmar-10-4491],[@b46-cmar-10-4491] However, the studies were inconclusive because of small sample sizes and inconsistencies in results. Therefore, to evaluate the relationship between HE4 expression and prognosis of cancer patients, we conducted this meta-analysis to mitigate sample size problems of individual studies and enhance the statistical power.

In the present meta-analysis, we analyzed 29 studies, including 3,564 patients, with OS data from 23 studies, DFS data from eight studies, and PFS data from eleven studies. The results indicated that there was no significant difference in the OS, DFS, and PFS outcomes based on HE4 expression status. There was significant heterogeneity in OS across the included studies. In order to ascertain the reason for the heterogeneity, we performed sensitivity analyses, and the results showed that the stable pooled HR was not significantly affected by any individual study. However, subgroup analyses revealed that the heterogeneity may have been due to the HR estimate methods used. Differences in the baseline characteristics of patients and in the HE4 expression cutoff values may have also contributed to the observed heterogeneity. However, for want of relevant data, it was not possible to determine the contribution of each of the above factors to the heterogeneity. In addition, we also found that the correlation between HE4 expression and OS of cancer patients was not affected by race, tumor type, sample source, detection method, or HR estimation method, and we therefore believe that HE4 may serve as a reliable and novel parameter for prognostication and a promising target for anticancer therapy in cancers.

Several previous meta-analyses have been conducted to research the association between HE4 expression and diagnosis and prognosis of cancer patients. For example, Zhong et al[@b47-cmar-10-4491] identified eight studies that involved 1,412 lung cancer patients and showed that high serum HE4 level was a marker of poor prognosis in lung cancer patients, particularly in patients of Asian origin. Compared with previous studies, our meta-analysis has several limitations as well as advantages. Our study is the first meta-analysis to review the role of HE4 in the OS, DFS, and PFS in several cancer types. In addition, to ensure the reliability of results, we have increased the number of studies included in the analysis.

Although we made every effort to conduct a comprehensive analysis, our study has several limitations. First, we tried to analyze the association between HE4 expression and prognosis in all cancer types, but the majority of included studies focused on endometrial cancer, ovarian cancer, or lung cancer. Hence, suitably designed larger future studies are needed to confirm our results. Second, when we evaluated the relationship between OS and HE4 expression, there was obvious publication bias, possibly because positive results are more likely to be published than are negative results. Last, the cutoff value for HE4 expression differed between studies, which may have led to heterogeneity. A standardized baseline value to designate positive/high HE4 expression status is thus needed. Meanwhile, the collection time and survival times were not standard, and this may be one of the sources of heterogeneity.

Conclusion
==========

We found that increased expression of HE4 indicated poor survival outcomes in patients with cancer. Therefore, HE4 is a potential novel prognostic factor in cancer patients.
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###### 

Main characteristics of all studies included in the meta-analysis

  Study                                        Year   Patient source               Number of patients   Tumor types   Method   Sample   Cutoff                                                                                                                                Outcome   M/U   HR (95% CI)          Quality
  -------------------------------------------- ------ ---------------------------- -------------------- ------------- -------- -------- ------------------------------------------------------------------------------------------------------------------------------------- --------- ----- -------------------- ---------
                                                                                                                                                                                                                                                                                                                   
  Stiekema et al[@b7-cmar-10-4491]             2017   Netherlands                  88                   EC            ECLIA    Blood    60 pmol/L for women \<40 years, 75 pmol/L for patients between 40 and 60 years of age, and 90 pmol/L for patients \>60 years of age   OS        M     7.37 (2.16--25.1)    9
  Orsaria et al[@b14-cmar-10-4491]             2016   Italy                        105                  OC            IHC      Tissue   H-score value \>1                                                                                                                     OS        M     1.82 (0.81--4)       8
  Aarenstrup Karlsen et al[@b8-cmar-10-4491]   2016   Denmark                      198                  OC            IHC      Tissue   --                                                                                                                                    OS        U     1.44 (1.01--2.0)     8
                                                                                                                                                                                                                                                                              PFS             1.49 (1.06--2.11)    
  Lan et al[@b15-cmar-10-4491]                 2015   People's Republic of China   218                  LC            EIA      Blood    20.5 ng/mL                                                                                                                            OS        M     3.78 (2.23--7.34)    8
  Deng et al[@b16-cmar-10-4491]                2015   People's Republic of China   65                   EC            IHC      Tissue   --                                                                                                                                    OS        U     2.51 (0.66--9.53)    7
  Li et al[@b17-cmar-10-4491]                  2015   People's Republic of China   102                  EC            IHC      Tissue   H-score value \>2                                                                                                                     OS        U     1.85 (0.37--9.28)    6
  Lee et al[@b18-cmar-10-4491]                 2015   United States of America     53                   OC            --       Tissue   --                                                                                                                                    OS        U     1.72 (0.87--3.46)    6
  Lamy et al[@b9-cmar-10-4491]                 2015   France                       346                  LC            EIA      Blood    140 pm                                                                                                                                OS        U     1.96 (1.53--2.53)    8
  Guo et al[@b19-cmar-10-4491]                 2015   United States of America     243                  GC            IHC      Tissue   H-score value \>1                                                                                                                     OS        U     1.62 (1.00--2.62)    7
  Lou et al[@b20-cmar-10-4491]                 2014   United States of America     153                  LC            EIA      Blood    65--83 pm                                                                                                                             OS        U     1.08 (0.87--1.36)    6
                                                                                                                                                                                                                                                                              PFS             0.95 (0.78--1.17)    
  Jiang et al[@b21-cmar-10-4491]               2014   People's Republic of China   100                  LC            EIA      Blood    7.26 ng/mL                                                                                                                            OS        M     3.65 (2.75--11.98)   7
  Brennan et al[@b22-cmar-10-4491]             2014   Australia                    373                  EC            CMIA     Blood    H-score \>75%                                                                                                                         DFS       M     2.40 (1.19--4.38)    9
  Zhang et al[@b23-cmar-10-4491]               2014   People's Republic of China   191                  LC            EIA      Blood    91.63 pmol/L                                                                                                                          OS        M     2.15 (1.49--3.12)    7
  Braicu et al[@b24-cmar-10-4491]              2014   Germany                      73                   OC            ECLIA    Blood    250 pm                                                                                                                                OS        U     3.33 (1.03--10.7)    6
  Zheng et al[@b25-cmar-10-4491]               2013   People's Republic of China   112                  OC            EIA      Blood    415.5 pmol/L                                                                                                                          OS        U     2.17 (1.11--4.23)    8
  Liu et al[@b26-cmar-10-4491]                 2013   People's Republic of China   169                  LC            EIA      Blood    83.90 pm                                                                                                                              OS        M     2.2 (0.8--5.9)       7
  Zanotti et al[@b27-cmar-10-4491]             2012   Italy                        190                  EC            CMIA     Blood    51 pm                                                                                                                                 OS        M     2.78 (1.16--6.63)    9
                                                                                                                                                                                                                                                                              DFS             2.49 (1.13--5.49)    
                                                                                                                                                                                                                                                                              PFS             2.66 (1.10--6.45)    
  Yamashita et al[@b28-cmar-10-4491]           2012   Japan                        74                   LC            EIA      Blood    50.3 pm                                                                                                                               DFS       U     3.28 (0.57--18.84)   7
  Trudel et al[@b29-cmar-10-4491]              2012   Canada                       136                  OC            CMIA     Blood    394 pmol/L                                                                                                                            OS        M     1.67 (1.08--2.59)    9
                                                                                                                                                                                                                                                                              PFS             1.32 (0.87--1.99)    
  Mutz-Dehbalaie et al[@b30-cmar-10-4491]      2012   Austria                      183                  EC            CMIA     Blood    81 pmol/L                                                                                                                             OS        M     2.41 (1.17--4.97)    8
                                                                                                                                                                                                                                                                              DFS             1.59 (0.82--3.08)    
  Kong et al[@b31-cmar-10-4491]                2012   Korea                        80                   OC            EIA      Blood    98.7 pm                                                                                                                               PFS       M     1.47 (1.02--2.1)     8
  Kalapotharakos et al[@b32-cmar-10-4491]      2012   Sweden                       312                  OC            EIA      Blood    405 pm                                                                                                                                OS        M     2.02 (1.1--3.8)      9
  Hu et al[@b33-cmar-10-4491]                  2012   People's Republic of China   76                   OC            EIA      Blood    208 pmol/L                                                                                                                            PFS       U     1.72 (0.92--3.21)    6
  Steffensen et al[@b34-cmar-10-4491]          2011   Denmark                      139                  OC            EIA      Blood    140 pm                                                                                                                                OS        M     3.17 (1.41--7.10)    9
                                                                                                                                                                                                                                                                              PFS             1.77 (1.03--3.04)    
  Yamashita et al[@b35-cmar-10-4491]           2011   Japan                        137                  LC            IHC      Tissue   H-score \>75%                                                                                                                         OS        M     5.5 (1.8--17.2)      8
                                                                                                                                                                                                                                                                              DFS             3.7 (1.7--8.4)       
  Paek et al[@b36-cmar-10-4491]                2011   Korea                        45                   OC            EIA      Blood    70 pm                                                                                                                                 PFS       M     2.24 (1.14--6.84)    8
  Han et al[@b37-cmar-10-4491]                 2011   United States of America     23                   OC            EIA      Blood    74 pm                                                                                                                                 PFS       U     1.97 (0.61--6.39)    7
  Bignotti et al[@b38-cmar-10-4491]            2011   Italy                        153                  EC            EIA      Blood    --                                                                                                                                    OS        U     3.74 (0.43--32.45)   8
                                                                                                                                                                                                                                                                              PFS             1.78 (0.30--10.44)   
                                                                                                                                                                                                                                                                              DFS             2.43 (0.87--6.77)    
  Bandiera et al[@b39-cmar-10-4491]            2011   Italy                        98                   OC            CMIA     Blood    43.8 pm                                                                                                                               OS        M     3.98 (1.35--11.75)   8
                                                                                                                                                                                                                                                                              DFS             2.46 (1.09--5.56)    
                                                                                                                                                                                                                                                                              PFS             2.77 (1.12--6.85)    

**Abbreviations:** M, multivariate analysis; U, univariate analysis; HR, hazard ratio; EC, endometrial cancer; OC, ovarian cancer; LC, lung cancer; GC, gastric cancer; ECLIA, electrochemiluminescence immunoassay assay; IHC, immunohistochemistry; EIA, enzyme immunoassay assay; CMIA, chemiluminescent microparticle immunoassay; OS, overall survival; DFS, disease-free survival; PFS, progression-free survival.

###### 

Main meta-analysis results for OS

  Analysis                 Number of studies   Number of patients   Model    HR (95% CI)          *P*-value   Heterogeneity   
  ------------------------ ------------------- -------------------- -------- -------------------- ----------- --------------- -------
                                                                                                                              
  OS                       23                  3,564                Random   2.15 (1.77--2.62)    0.000       55.6            0.001
  Race                                                                                                                        
   White                   15                  2,470                Random   1.92 (1.53--2.39)    0.000       55.9            0.004
   Asian                   8                   1,094                Fixed    2.62 (2.06--3.35)    0.000       0.0             0.587
  Tumor types                                                                                                                 
   EC                      6                   781                  Fixed    2.91 (1.86--4.53)    0.000       0.0             0.719
   OC                      9                   1,226                Fixed    1.82 (1.50--2.22)    0.000       0.0             0.515
   LC                      7                   1,314                Random   2.31 (1.54--3.47)    0.000       82.4            0.000
   GC                      1                   243                  --       1.62 (1.00--2.62)    --          --              --
  Sample                                                                                                                      
   Blood                   16                  2,661                Random   2.34 (1.82--3.02)    0.000       65.7            0.000
   Tissue                  7                   903                  Fixed    1.67 (1.32--2.11)    0.000       0.0             0.488
  Method                                                                                                                      
   ECLIA                   2                   161                  Fixed    4.86 (2.09--11.34)   0.000       0.0             0.358
   IHC                     6                   850                  Fixed    1.66 (1.30--2.13)    0.000       8.1             0.365
   EIA                     10                  1,893                Random   2.20 (1.61--3.01)    0.000       73.1            0.000
   CMIA                    4                   607                  Fixed    2.10 (1.51--2.91)    0.000       0.0             0.402
  HR estimate                                                                                                                 
   Multivariate analysis   13                  2,066                Fixed    2.47 (2.05--2.97)    0.000       13.4            0.310
   Univariate analysis     10                  1,498                Fixed    1.50 (1.31--1.71)    0.000       47.8            0.045

**Abbreviations:** HR, hazard ratio; OS, overall survival; EC, endometrial cancer; OC, ovarian cancer; LC, lung cancer; GC, gastric cancer; ECLIA, electrochemiluminescence immunoassay assay; IHC, immunohistochemistry; EIA, enzyme immunoassay assay; CMIA, chemiluminescent microparticle immunoassay.
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